NEW YORK, Feb. 5, 2026 /PRNewswire/ — Briya, the health AI technology company redefining healthcare research, today announced the appointment of Brian CreightonNEW YORK, Feb. 5, 2026 /PRNewswire/ — Briya, the health AI technology company redefining healthcare research, today announced the appointment of Brian Creighton

Briya Appoints Brian Creighton to Accelerate Growth in AI-Driven Healthcare Data

2026/02/05 22:00
3 min read

NEW YORK, Feb. 5, 2026 /PRNewswire/ — Briya, the health AI technology company redefining healthcare research, today announced the appointment of Brian Creighton as Executive Director of Client Strategy. The appointment comes as Briya scales its presence in the U.S. to empower life sciences organizations and healthcare providers to collaborate on data-driven research and development.

Bringing more than two decades of experience spanning medical imaging and AI, Brian will lead Briya’s strategic partnerships and business expansion, addressing the healthcare industry’s critical need for secure and seamless access to high-quality real-world data to drive research and innovation. A key focus will be driving the adoption of Briya AIRE, the company’s clinical-grade AI platform that accelerates medical and epidemiological research.

“Brian’s deep expertise and proven track record in expanding the implementation of AI technologies will be instrumental as we navigate our next phase of growth,” said David Lazerson, Co-founder and CEO of Briya. “His understanding of the complexities of operating in the healthcare space will prove essential as we continue to deliver a platform that accelerates the pace of discovery and innovation.”

Brian joins Briya having spent more than 20 years driving business development initiatives within the healthcare ecosystem. Prior to Briya, he was VP of Sales at Merative, focusing on delivering cloud native imaging solutions to healthcare organizations. Before that, he held multiple leadership roles at IBM Watson Health, where he oversaw sales operations, managed complex software implementation projects, and led teams in the Health Information Exchange sector.

“I’m excited to join Briya at a pivotal moment for the company,” said Brian Creighton. “As demand grows for secure, interoperable, and actionable health data, Briya is solving one of the most critical challenges in healthcare innovation. I look forward to bringing my experience to help expand Briya’s impact across life sciences, research, and care delivery.”

Brian is currently representing Briya at the SCOPE Summit, taking place this week (February 2–5, 2026) in Orlando, Florida.

About Briya

Briya is a healthcare technology company dedicated to supporting vital medical and biopharma research and innovation with AI and data. Briya AIRE™, the first AI research engine built specifically for clinical and biomedical research, serves as an AI assistant across academia and the pharmaceutical industry. It can collect and analyze complex clinical data, generating insights that can be used to design cohorts, validate endpoints and meet key development milestones. With full anonymization and a federated data approach, Briya accelerates the path to discoveries while maintaining the highest standards of security, compliance, and trust.

For more information, follow us on LinkedIn and X, or visit https://briya.com.

Media Contact:
FINN Partners for Briya
Danny Sudwarts
[email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/briya-appoints-brian-creighton-to-accelerate-growth-in-ai-driven-healthcare-data-302679975.html

SOURCE Briya

Market Opportunity
Union Logo
Union Price(U)
$0,00157
$0,00157$0,00157
+1,15%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.